CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 130 enrolled
Drug / intervention
EIDD-2801 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04392219
NCT04392219Phase 1Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers

Ridgeback Biotherapeutics, LP·interventional·Posted May 18, 2020·Updated Jul 19, 2021

In Brief

A Phase 1 clinical trial evaluating EIDD-2801 and Placebo for Coronavirus. Completed, enrolled 130 participants across 1 site.

Detailed Summary

This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMay 18, 2020
Enrollment StartApr 10, 2020
Primary CompletionAug 11, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.1 years ago

Interventions

EIDD-2801drug

Part 1: Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo. Part 2: Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner. Part 3: Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.

Placebodrug

Part 1: Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo. Part 3: Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.